| 13.72 0.02 (0.15%) | 04-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.43 | 1-year : | 19.58 |
| Resists | First : | 14.92 | Second : | 16.77 |
| Pivot price | 13.36 |
|||
| Supports | First : | 11.94 | Second : | 9.94 |
| MAs | MA(5) : | 13.7 |
MA(20) : | 13.43  |
| MA(100) : | 55.25 |
MA(250) : | 46 |
|
| MACD | MACD : | -6 |
Signal : | -8 |
| %K %D | K(14,3) : | 85.7 |
D(3) : | 84.5 |
| RSI | RSI(14): 14.6 |
|||
| 52-week | High : | 73.05 | Low : | 11.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RNA ] has closed below upper band by 22.3%. Bollinger Bands are 91.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.94 - 14 | 14 - 14.06 |
| Low: | 13.43 - 13.51 | 13.51 - 13.58 |
| Close: | 13.6 - 13.71 | 13.71 - 13.83 |
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Wed, 08 Apr 2026
T. Rowe Price holds 1.55M Atrium shares (10.0%) (NASDAQ: RNA) - Stock Titan
Thu, 19 Mar 2026
Novartis acquisition spin-off pioneers RNA therapeutics for the heart - Pharma Voice
Mon, 02 Mar 2026
Atrium Therapeutics Launches with $270M to Advance RNA Therapies for Rare Genetic Cardiomyopathies - HLTH
Mon, 02 Mar 2026
Atrium Tx launches with Avidity's RNA ticker and cardio assets - BioWorld News
Sun, 01 Mar 2026
Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions - MedCity News
Sat, 28 Feb 2026
Atrium Therapeutics Stock Pre-Market (-4.5%): Launch as Public Company Post-Spin-Off - Trefis
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 1.504e+007 (%) |
| Held by Institutions | 2.7 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.931e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -265.9 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 387.8 % |
| Return on Equity (ttm) | -399.3 % |
| Qtrly Rev. Growth | 1.862e+007 % |
| Gross Profit (p.s.) | 466.66 |
| Sales Per Share | -34.89 |
| EBITDA (p.s.) | -5.02495e+008 |
| Qtrly Earnings Growth | -4.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.4 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 432800 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|